Your browser is no longer supported. Please, upgrade your browser.
BMRN BioMarin Pharmaceutical Inc. monthly Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-1.08 Insider Own0.60% Shs Outstand163.10M Perf Week-4.08%
Market Cap13.88B Forward P/E- EPS next Y-1.36 Insider Trans-5.13% Shs Float161.80M Perf Month0.73%
Income-171.80M PEG- EPS next Q-0.44 Inst Own100.00% Short Float4.72% Perf Quarter18.11%
Sales890.60M P/S15.58 EPS this Y-17.30% Inst Trans-1.31% Short Ratio4.22 Perf Half Y-25.23%
Book/sh14.18 P/B6.00 EPS next Y35.20% ROA- Target Price114.79 Perf Year-26.60%
Cash/sh2.80 P/C30.37 EPS next 5Y25.00% ROE- 52W Range62.12 - 151.75 Perf YTD-18.78%
Dividend- P/FCF- EPS past 5Y-21.30% ROI- 52W High-43.93% Beta0.95
Dividend %- Quick Ratio1.80 Sales past 5Y18.80% Gross Margin82.90% 52W Low36.98% ATR3.93
Employees2158 Current Ratio2.60 Sales Q/Q16.40% Oper. Margin-14.10% RSI (14)46.67 Volatility3.61% 4.56%
OptionableYes Debt/Eq0.29 EPS Q/Q- Profit Margin- Rel Volume0.56 Prev Close86.90
ShortableYes LT Debt/Eq0.29 EarningsApr 28 AMC Payout- Avg Volume1.81M Price85.09
Recom1.80 SMA20-2.73% SMA500.84% SMA200-17.38% Volume1,012,384 Change-2.08%
Mar-08-16Upgrade Robert W. Baird Neutral → Outperform $110
Mar-03-16Reiterated Stifel Buy $105 → $107
Feb-29-16Reiterated Wedbush Neutral $117 → $105
Feb-26-16Reiterated RBC Capital Mkts Outperform $155 → $125
Feb-16-16Upgrade Stifel Hold → Buy $105
Jan-20-16Initiated Credit Suisse Outperform
Jan-19-16Reiterated Wedbush Neutral $125 → $117
Nov-25-15Reiterated Oppenheimer Perform $119 → $115
Nov-18-15Initiated Goldman Buy
Oct-05-15Reiterated Wedbush Neutral $131 → $137
Oct-02-15Initiated Raymond James Outperform $148
Sep-01-15Initiated Raymond James Outperform $148
Jul-08-15Reiterated RBC Capital Mkts Outperform $145 → $155
Jun-19-15Downgrade Robert W. Baird Outperform → Neutral $125 → $133
Jun-18-15Reiterated Sun Trust Rbsn Humphrey Buy $151 → $170
Jun-18-15Reiterated RBC Capital Mkts Outperform $125 → $145
Jun-18-15Reiterated Piper Jaffray Overweight $123 → $147
Jun-18-15Reiterated Jefferies Buy $135 → $150
Jun-18-15Reiterated Deutsche Bank Buy $140 → $156
Jun-18-15Reiterated Canaccord Genuity Buy $115 → $150
May-03-16 09:59AM  BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
08:25AM  BioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, Experimental Treatment for a Form of Batten Disease GlobeNewswire
May-02-16 09:06AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report EDGAR Online
May-01-16 10:50AM  Analysts Make Major Changes to Top Biotech Ratings at 24/7 Wall St.
Apr-29-16 01:32PM  BioMarin (BMRN) Reports Narrower-than-Expected Q1 Loss Zacks
03:13AM  Edited Transcript of BMRN earnings conference call or presentation 28-Apr-16 8:30pm GMT Thomson Reuters StreetEvents
Apr-28-16 04:53PM  BioMarin reports 1Q loss AP
04:22PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:01PM  BioMarin Announces First Quarter 2016 Financial Results GlobeNewswire
02:35PM  Why Sarepta Therapeutics Inc. Is Up Big Today at Motley Fool
07:07AM  Q1 2016 Biomarin Pharmaceutical Inc Earnings Release - After Market Close CCBN
07:00AM  Sanofi Presses Medivation to Hold Talks After $9.3B Offer at TheStreet
Apr-27-16 08:57AM  Should You Buy BioMarin Pharmaceutical (BMRN) Ahead of Earnings? Zacks
08:21AM  Despite Pleas, FDA Panel Shuns Drug at Motley Fool
Apr-26-16 11:50AM  This Rare Childrens Disease Drug Is Pitting Patients Against the FDA at Fortune
10:05AM  4 Biotechs That Will Escape Weak Seasonal Trends for the Sector at 24/7 Wall St.
Apr-25-16 02:42PM  5 Biotech Stocks to Bet on This Earnings Season Zacks
09:39AM  BioMarin (BMRN) Q1 Earnings: Stock Likely to Beat Estimates Zacks
Apr-21-16 04:30PM  BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of MPS IIIB (Sanfilippo B Syndrome) GlobeNewswire
11:06AM  XBIs Large Caps: BioMarin Gives Update on Gene Therapy Study Market Realist
10:35AM  Sarepta: That Really Wasn't Good at Barrons.com
06:00AM  Jim Cramer's Top Takeaways: Intel, BioMarin Pharmaceuticals at TheStreet
Apr-20-16 07:26PM  Cramer Remix: The most dangerous stock group at CNBC
06:06PM  XBI Large Caps: BioMarin to Announce Its 1Q16 Results on April 28 Market Realist
04:49PM  [$$] BioMarin: This Earnings Dynamo Is Priced to Buy at Barrons.com
11:11AM  BioMarin Pharmaceutical Stock Rises On Favorable Phase 2 Study Of Vosoritide Benzinga
11:05AM  Can BioMarin Make Treating Hemophilia More Affordable? at 24/7 Wall St.
10:37AM  BioMarin Provides Program Update on Vosoritide in Achondroplasia GlobeNewswire
10:27AM  BioMarin Gene Therapy For Hemophilia Scores In Trial; Stock Jumps at Investor's Business Daily
10:07AM  Why BioMarin is Soaring at Barrons.com
08:52AM  BioMarin announces 'encouraging' early-stage hemophilia therapy data at MarketWatch
08:30AM  BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program GlobeNewswire
Apr-18-16 10:21AM  BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
08:30AM  BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on April 20th in New York GlobeNewswire
08:18AM  Will MS Franchise Sales Boost Biogen's (BIIB) 1Q Earnings?
Apr-13-16 03:39PM  3 Biotech Takeover Targets That Could Get Bought Soon at Motley Fool
Apr-12-16 08:30AM  BioMarin to Host First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, April 28 at 4:30pm ET GlobeNewswire
Apr-11-16 10:01AM  3 Ways Pfizer Can Improve Shareholder Value Without Allergan at Motley Fool
Apr-09-16 10:43AM  Why Sarepta Therapeutics Inc. Soared 44% Higher in March at Motley Fool
Apr-08-16 09:08AM  How Could Baxalta Acquisition Become a Catalyst for Shire?
Apr-07-16 04:04PM  How Does Incytes Valuation Compare to Peers?
12:00PM  BioMarin (BMRN) Stock is the 'Chart of the Day' at TheStreet
11:59AM  3 Drug Developers Pfizer Could Go After Now That the Allergan Deal Is Officially Dead at Motley Fool
11:30AM  Why Sarepta Therapeutics Surged 20% in Wednesday Trading?
Apr-06-16 01:04AM  Understanding Acthars Big Contribution to Mallinckrodts Top-line +7.61%
Apr-01-16 06:20AM  Sell These 5 Toxic Stocks Now, Before It's Too Late at TheStreet
Mar-29-16 09:44AM  The 5-Minute Guide to BioMarin Pharmaceutical Stock at Motley Fool
07:00AM  Healthcare: Drug Reform Worries Are Overblown at Morningstar
Mar-28-16 11:50AM  BioMarin (BMRN) BMN 270 Gets Orphan Drug Status in EU
Mar-24-16 03:15PM  Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation
08:38AM  BioMarin Receives European Orphan Drug Designation for BMN 270, First Investigational AAV-Factor VIII Gene Therapy for Patients with Hemophilia A at noodls
08:30AM  BioMarin Receives European Orphan Drug Designation for BMN 270, First Investigational AAV-Factor VIII Gene Therapy for Patients with Hemophilia A GlobeNewswire
Mar-23-16 11:15AM  Jefferies Identifies 5 Top Biotech Stocks for Huge Upside at 24/7 Wall St.
07:00AM  8 Wide-Moat Stocks of Tomorrow at Morningstar
Mar-22-16 01:27PM  Biomarin Meets Primary Endpoint of Phase 3 Study of Pegvalise +6.70%
09:30AM  BioMarin (BMRN) Down on Phase III Data on Pegvaliase
Mar-21-16 11:36AM  My trading is garbage
11:15AM  BioMarin PKU Drug Shows Mixed Results in Pivotal Study at TheStreet
09:05AM  BioMarin Sinks Despite Meeting Primary Endpoint at 24/7 Wall St.
06:22AM  BioMarin drug for genetic disorder succeeds in late-stage study Reuters
Mar-17-16 08:12AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : March 17, 2016
Mar-16-16 03:10PM  Valeants Preliminary 4Q15 Revenue and Earnings
Mar-15-16 09:08PM  Rare Disease Portfolio Helped Sanofi to Offset Falling Diabetes Sales
03:36PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Financial Statements and Exhibits
Mar-14-16 08:35AM  4 Top Jefferies Growth Stocks to Buy With Big Upside Potential at 24/7 Wall St.
Mar-13-16 10:35AM  5 Key FDA Decisions Expected in March at 24/7 Wall St.
Mar-12-16 04:18PM  Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem at TheStreet
Mar-10-16 01:15PM  FDA sets new date for panel review of Sarepta's muscle drug Reuters
Mar-08-16 04:05PM  Jim Cramer Says BioMarin Is the Last Bear Market at TheStreet
11:27AM  Jim Cramer: Bear Markets in Many Sectors Have Ended at TheStreet
09:53AM  Cramer's Stop Trading: Bear markets over?
09:25AM  Top Biotech Stocks Dominate Jefferies Growth Stocks to Buy This Week at 24/7 Wall St.
05:46AM  Biomarin Pharm upgraded by Robert W. Baird
Mar-07-16 12:26PM  AbbVie Bolsters Immunology Business, Acquires Boehringer Drug
10:07AM  Kuvan and Pegvaliase as BioMarins Potential Valuation Drivers
08:07AM  BioMarins Naglazyme Sales Dipped by 31.3% Last Year
Mar-04-16 01:04PM  BIOMARIN PHARMACEUTICAL INC Financials
Mar-03-16 06:32PM  What Are Analysts Recommending for BioMarin?
06:32PM  Analyzing BioMarins Performance on a Price-to-Sales Basis
03:21PM  BioMarin: New Drug, New Growth Driver at Barrons.com
02:11PM  Biomarin Drug Provides 'Substantial Benefit' to Kids with Rare, Fatal Brain Disease at TheStreet
11:32AM  BioMarin Stock Up As Drug Slows Progress Of Deadly Rare Disease
10:05AM  'Kids on the cusp': Early data moves BioMarin against a child killer at bizjournals.com
09:39AM  BioMarin Pharmaceutical, Inc. Value Analysis (NASDAQ:BMRN) : March 3, 2016
08:30AM  BioMarin to Attend Three Upcoming Investor Conferences in March GlobeNewswire
Mar-02-16 07:05PM  BioMarin Announces Positive Data From Cerliponase Alfa Program for Treatment of CLN2 Disease, a Form of Batten Disease, at 12th Annual WORLDSymposium(TM) 2016 GlobeNewswire
11:15AM  Palo Altos Top Picks for This Year Following Impressive 2015 Returns at Insider Monkey
08:11AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : March 2, 2016
Mar-01-16 09:07PM  What Do Analysts Expect from Alexion? +6.96%
09:06PM  Vertex Hopes Label Expansion Will Bring Growth for Kalydeco
05:43PM  BioMarin Receives Orphan Drug Designation From FDA for First AAV-Factor VIII Gene Therapy, BMN 270, for Patients With Hemophilia A GlobeNewswire
02:11PM  JPMorgan's 7 Best Stock Picks With Near-Term Catalysts at TheStreet
02:06PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
10:45AM  Duchenne patient advocacy group lauds Sarepta for transparency at bizjournals.com
Feb-29-16 12:11PM  BioMarin Faces a Key Test of Rare Disease Pipeline at TheStreet
09:05AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-K, Annual Report
08:30AM  BioMarin Announces BioMarin RareConnections(TM) Rebranding and Consolidating BioMarins Comprehensive Support and Services for Eligible Rare Disease Patients GlobeNewswire
08:25AM  BioMarin Announces 21 Presentations at 12th Annual WORLDSymposium 2016 February 29-March 4 in San Diego, California: 6 Oral and 15 Poster GlobeNewswire
Feb-28-16 02:31PM  5 Trade ideas for Monday: Capital One, Ashland, Tyco, Fifth Third & BioMarin
10:45AM  How Analysts Changed Views on BioMarin After Earnings at 24/7 Wall St.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; and Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Kyndrisa, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 044, BMN 045, and BMN 053 for DMD treatment; cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis; and and BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate for the treatment of hemophilia A. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as alpha-N-acetyglucosaminidase. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerApr 06Option Exercise14.391,50021,585395,221Apr 07 08:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Option Exercise14.391,50021,585393,721Apr 07 08:49 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfficerMar 04Sale88.421,255110,97046,882Mar 07 08:45 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Sale86.124,623398,12049,688Mar 02 08:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 01Sale84.2810,000842,769340,500Mar 02 08:38 PM
GREY MICHAEL GDirectorFeb 22Option Exercise38.597,500289,42533,750Feb 23 04:41 PM
GREY MICHAEL GDirectorFeb 22Sale80.007,500600,00026,250Feb 23 04:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 30Sale94.741,00094,74425,758Dec 02 06:58 PM
GREY MICHAEL GDirectorNov 16Option Exercise38.597,500289,42533,750Nov 18 04:49 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerNov 16Option Exercise39.0620,000781,20048,229Nov 18 04:03 PM
LAWLIS V BRYANDirectorNov 16Option Exercise17.337,500129,97519,350Nov 18 05:10 PM
LAWLIS V BRYANDirectorNov 16Sale104.261,050109,46811,850Nov 18 05:10 PM
GREY MICHAEL GDirectorNov 16Sale104.277,500782,05426,250Nov 18 04:49 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerNov 16Sale104.3020,0002,085,91828,229Nov 18 04:03 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 02Sale117.56263,05735,605Nov 06 05:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 15Sale108.241,000108,24126,758Oct 19 01:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 14Sale131.431,000131,43227,758Sep 16 08:09 PM
HERON ELAINE JDirectorSep 08Option Exercise21.5115,000322,65035,625Sep 25 12:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 12Sale134.721,500202,08328,758Aug 13 10:40 AM
Ajer Jeffrey RobertSVP, Chief Commercial OfJul 20Option Exercise63.103,000189,30038,605Jul 22 03:21 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJul 20Sale150.003,000450,00035,605Jul 22 03:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 07Sale139.071,500208,60030,258Jul 09 05:06 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 05Sale122.301,649201,66928,229Jun 08 06:09 PM
FUCHS HENRY JEVP, Chief Medical OfficerJun 05Sale122.321,864228,00172,846Jun 08 06:06 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 04Sale122.351,362166,64635,605Jun 08 05:43 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 01Sale123.7637746,65738,455Jun 03 08:23 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 01Sale124.163,945489,81131,679Jun 03 08:27 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 29Sale126.151,578199,06535,624Jun 03 08:27 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 26Sale126.551,625205,64739,245May 26 07:52 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 18Sale124.781,864232,58476,746May 19 07:21 PM
Davis George EricSVP, General CounselMay 18Sale125.262,558320,41569,226May 19 07:18 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 18Sale130.0034,0784,430,14041,507May 28 05:10 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 13Sale121.371,434174,03880,646May 14 06:54 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 11Sale121.642,869348,98883,646May 12 07:27 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 06Option Exercise33.9333,6311,141,21576,664May 08 05:49 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 06Sale119.1434,0194,053,04242,645May 08 05:49 PM